Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MPC-2130

Small molecule · developed by Myriad Therapeutics

Phase 1 Most advanced trial (none active)
MYGN Developer
1 Registered trials

What is MPC-2130?

MPC-2130 is a small molecule that induces apoptosis in tumor cells, with effects including phosphatidylserine externalization, cytochrome C release from mitochondria, caspase activation and DNA fragmentation. It is not a substrate for several multidrug resistance efflux transporters, and is being studied in cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Pathways
apoptosis
Therapy area
Oncology
Developer
Myriad Therapeutics, Inc. (MYGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00387153 Phase 1 Cancer Terminated MYGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cancer

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MYGN page.

Follow MYGN, the company behind MPC-2130

See MYGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MYGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.